News

TB R&D Weekly Update: Podcast Interview with Dr. Edward Nardell

Dr. Edward Nardell, Partners in Health
Dr. Edward Nardell, Partners in Health

Listen to Edward Nardell Podcast

Summary: This week, we feature an interview with Dr. Edward Nardell who is a pulmonologist with a special interest in tuberculosis; trained in pulmonary medicine at Massachusetts General Hospital with additional research training at Boston University School of Medicine. His principal academic appointment is as associate professor of medicine, Harvard Medical School, with secondary parallel appointments in the Department of Global Health and Social Medicine and Harvard School of Public Health. In 2002 he joined Partners In Health as Director of Tuberculosis Research.

His research interests include the control of multidrug-resistant tuberculosis (MDR-TB) in Peru, Russia, and other high-burden countries, with a special research interest in airborne TB transmission and control. Dr. Nardell is currently conducting a research project in South Africa studying the transmission of MDR-TB using large numbers of guinea pigs to quantify the infectiousness of MDR-TB patients and the effectiveness of various control interventions, including ultraviolet germicidal irradiation. (Click here to view full bio) During the interview, we discuss with Dr. Nardell his background and interest in TB, the Airbourne Infections Research (AIR) Facility, his thoughts on the MDR-TB epidemic, and his current research focus.

Additional TB R&D News:

CDC: Latent TB treatment may now be done in 3 months

Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin Resistant Mycobacterium tuberculosis through Efflux

Metabolite-enabled eradication of bacterial persisters by aminoglycosides

New Findings Reported from Georgia Institute of Technology Describe Advances in Microbial Drug Resistance

More News
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...
23 Mar 2022
On March 21st, 2022, the World Health Organization (WHO) updated its guidelines on treatment of non-severe TB disease in children and adolescents. The new guidelines recommend a shorter duration of treatment and reduces the standard of care which is currently 6 months of therapy down to 4 months...